Pregabalin Capsule
Product Images NDC 70518-2762

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2762). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 50 mg capsule label showing a quantity of 90 capsules. The label includes the DEA schedule C-V, states 'RX ONLY', and is repackaged by Remedy Repack Inc. The manufacturing source is Novadoz Pharmaceuticals LLC, Piscataway, NJ. Additional information includes storage instructions and a QR code.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, with a multiplier for female patients. The formula includes variables for age in years, weight in kilograms, and serum creatinine in mg/dL, highlighting adjustment for female patients with a factor of 0.85.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different Pregabalin dosages and placebo. Four lines represent Pregabalin 200 mg, 100 mg, and 25 mg three times a day, and placebo, showing patient improvement trends across ranges of pain relief percentage.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier plot depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day (dashed line) with placebo (dotted line), showing higher patient improvement percentages across pain improvement thresholds for Pregabalin.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A Kaplan-Meier curve chart showing the percent of patients improved against percent improvement in pain from baseline for Pregabalin given at doses of 75 mg, 150 mg, and 300 mg two times a day, compared to placebo. The chart has four lines representing each group with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A survival-type curve graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). The vertical axis represents percent of patients improved, ranging from 0 to 100%, while the horizontal axis represents percent improvement in pain from baseline, from >0 to 100%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for pregabalin doses of 50 mg and 100 mg taken three times a day, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percent of patients improved. The graph shows curves for pregabalin 50 mg (solid line), pregabalin 100 mg (dashed line), and placebo (dotted line).*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart comparing responder rates (%) for Pregabalin across two studies (E1 and E3) at various dosages versus placebo. Study E1 shows increasing responder rates from placebo to 600 mg/day dosed BID (twice daily), while Study E3 compares placebo to 600 mg/day dosed BID and TID (three times daily). Percentages and sample sizes (N) are indicated for each group, with a note on statistical significance versus placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph showing seizure reduction (median percent change from baseline) on the y-axis versus dose (mg/day) on the x-axis for different Stukly dosing regimens. Four lines represent Stukly E1BID, E2BID, E3BID, and E3TID, with data points at doses 0, 50, 150, 300, and 600 mg/day and associated p-values indicating statistical significance.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

Kaplan-Meier type curve graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. The x-axis represents percent improvement in pain from baseline, ranging from greater than 0 to 100, and the y-axis shows the percent of patients improved, ranging from 0 to 100 percent. Four treatment groups are differentiated by line style.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The chart includes two lines: a solid line for Pregabalin and a dashed line for placebo, with the y-axis representing the estimated percentage of subjects without LTR and the x-axis representing days.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved with Pregabalin versus placebo over varying percentages of improvement from baseline to week 12 BOCF. The x-axis represents the percent improvement, while the y-axis shows the percent of subjects improved. The solid line indicates Pregabalin, and the dotted line indicates placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent improvement of subjects treated with Pregabalin versus placebo from baseline to week 16 using a BOCF method. The vertical axis represents the percent of subjects improved, and the horizontal axis shows percent improved from baseline to week 16, highlighting that Pregabalin has a higher percentage of subjects improved across the range compared to placebo.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin showing its molecular arrangement of atoms including carbon, hydrogen, nitrogen, and oxygen groups consistent with the active ingredient pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.